Milestone Pharmaceuticals Inc. – NASDAQ:MIST
Milestone Pharmaceuticals stock price today
$1.65
-0.5
-23.26%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Milestone Pharmaceuticals stock price monthly change
+37.82%
month
Milestone Pharmaceuticals stock price quarterly change
+37.82%
quarter
Milestone Pharmaceuticals stock price yearly change
+14.36%
year
Milestone Pharmaceuticals key metrics
Market Cap | 94.39M |
Enterprise value | 157.86M |
P/E | -2.84 |
EV/Sales | 31.57 |
EV/EBITDA | -1.77 |
Price/Sales | 32.60 |
Price/Book | 2.45 |
PEG ratio | -0.02 |
EPS | -1.33 |
Revenue | N/A |
EBITDA | -53.27M |
Income | -55.08M |
Revenue Q/Q | -100% |
Revenue Y/Y | -114.46% |
Profit margin | -904.22% |
Oper. margin | -1809.9% |
Gross margin | 0% |
EBIT margin | -1809.9% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMilestone Pharmaceuticals stock price history
Milestone Pharmaceuticals stock forecast
Milestone Pharmaceuticals financial statements
| Jun 2023 | 0 | -16.04M | |
|---|---|---|---|
| Sep 2023 | 0 | -15.08M | |
| Dec 2023 | -868.00K | -13.61M | 1568.08% |
| Mar 2024 | 0 | -10.35M |
| Sep 2025 | 4.61M | -13.50M | -292.75% |
|---|---|---|---|
| Oct 2025 | 1.7M | -18.05M | -1062.11% |
| Dec 2025 | 5M | -26.64M | -532.87% |
| Dec 2025 | 3.83M | -19.05M | -497.19% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 97019000 | 56.61M | 58.35% |
|---|---|---|---|
| Sep 2023 | 87116000 | 58.61M | 67.28% |
| Dec 2023 | 75226000 | 58.45M | 77.71% |
| Mar 2024 | 96001000 | 56.08M | 58.42% |
| Jun 2023 | -10.56M | -28.03M | -2.76M |
|---|---|---|---|
| Sep 2023 | -12.16M | -10.85M | 305K |
| Dec 2023 | -9.22M | 13.67M | 1K |
| Mar 2024 | -8.93M | -27.01M | 32.31M |
Milestone Pharmaceuticals alternative data
| Aug 2023 | 39 |
|---|---|
| Sep 2023 | 39 |
| Oct 2023 | 39 |
| Nov 2023 | 39 |
| Dec 2023 | 39 |
| Jan 2024 | 39 |
| Feb 2024 | 39 |
| Mar 2024 | 47 |
| Apr 2024 | 47 |
| May 2024 | 47 |
| Jun 2024 | 47 |
| Jul 2024 | 47 |
Milestone Pharmaceuticals other data
27.52%
-30.87%
of MIST is owned by hedge funds
23
-31
11.35M
-12.73M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 5000 | 0 |
| Sep 2022 | 1557346 | 1557346 |
| Oct 2022 | 54000 | 0 |
| Dec 2022 | 10000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BHARUCHA DAVID officer: Chief Medical Officer | Common Shares | 7,000 | $4.69 | $32,830 | ||
Purchase | BHARUCHA DAVID officer: Chief Medical Officer | Common Shares | 3,000 | $4.86 | $14,580 | ||
Purchase | LIEBERT DEBRA K. director | Common Shares | 4,000 | $5.26 | $21,040 | ||
Purchase | PASTERNAK RICHARD C director | Common Shares | 10,000 | $5.2 | $52,000 | ||
Purchase | LIEBERT DEBRA K. director | Common Shares | 10,000 | $5.29 | $52,900 | ||
Purchase | WILLS ROBERT JAMES director | Common Shares | 15,000 | $4.93 | $73,950 | ||
Purchase | TOMSICEK MICHAEL JOHN director | Common Shares | 15,000 | $5.32 | $79,800 | ||
Sale | RTW INVESTMENTS, LP 10 percent owner | Common Shares | 1,557,346 | $8.71 | $13,564,484 | ||
Purchase | RTW INVESTMENTS, LP 10 percent owner | Common Shares, no par value ("Common Shares") | 1,557,346 | $8.71 | $13,564,484 | ||
Option | TRUEX PAUL F director | Stock Option (right to buy) | 822 | $2.66 | $2,187 |
| Patent |
|---|
Application Filling date: 26 Jan 2022 Issue date: 12 May 2022 |
Application HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF Filling date: 26 Oct 2021 Issue date: 10 Feb 2022 |
Application Filling date: 22 Jun 2021 Issue date: 14 Oct 2021 |
Application HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF Filling date: 18 Mar 2021 Issue date: 8 Jul 2021 |
Application Filling date: 12 Nov 2020 Issue date: 4 Mar 2021 |
Application HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF Filling date: 13 Aug 2020 Issue date: 26 Nov 2020 |
Application Filling date: 9 Apr 2020 Issue date: 23 Jul 2020 |
Application HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF Filling date: 19 Dec 2019 Issue date: 23 Apr 2020 |
Application Filling date: 29 Aug 2019 Issue date: 19 Dec 2019 |
Application HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF Filling date: 17 May 2019 Issue date: 5 Sep 2019 |
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Stock Picks From Seeking Alpha's March 2025 New Analysts
Milestone Pharmaceuticals: Worthy Of A Dart Throw
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
Milestone Pharmaceuticals: Looking Attractive After Drop On Positive News
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
-
What's the price of Milestone Pharmaceuticals stock today?
One share of Milestone Pharmaceuticals stock can currently be purchased for approximately $1.65.
-
When is Milestone Pharmaceuticals's next earnings date?
Unfortunately, Milestone Pharmaceuticals's (MIST) next earnings date is currently unknown.
-
Does Milestone Pharmaceuticals pay dividends?
No, Milestone Pharmaceuticals does not pay dividends.
-
How much money does Milestone Pharmaceuticals make?
Milestone Pharmaceuticals has a market capitalization of 94.39M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 80% to 1M US dollars.
-
What is Milestone Pharmaceuticals's stock symbol?
Milestone Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "MIST".
-
What is Milestone Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Milestone Pharmaceuticals?
Shares of Milestone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Milestone Pharmaceuticals's key executives?
Milestone Pharmaceuticals's management team includes the following people:
- Mr. Joseph G. Oliveto Chief Executive Officer, Pres & Director(age: 57, pay: $646,380)
- Mr. Amit Hasija Chief Financial Officer & Executive Vice President of Corporation Devel.(age: 52, pay: $442,220)
- Dr. Francis Plat Chief Medical Officer(age: 67, pay: $437,990)
-
How many employees does Milestone Pharmaceuticals have?
As Jul 2024, Milestone Pharmaceuticals employs 47 workers.
-
When Milestone Pharmaceuticals went public?
Milestone Pharmaceuticals Inc. is publicly traded company for more then 6 years since IPO on 9 May 2019.
-
What is Milestone Pharmaceuticals's official website?
The official website for Milestone Pharmaceuticals is milestonepharma.com.
-
Where are Milestone Pharmaceuticals's headquarters?
Milestone Pharmaceuticals is headquartered at 1111 Dr. Frederik-Philips Boulevard, Montreal, QC.
-
How can i contact Milestone Pharmaceuticals?
Milestone Pharmaceuticals's mailing address is 1111 Dr. Frederik-Philips Boulevard, Montreal, QC and company can be reached via phone at +1 514 336 0444.
Milestone Pharmaceuticals company profile:
Milestone Pharmaceuticals Inc.
milestonepharma.comExchange:
NASDAQ
Full time employees:
47
Industry:
Biotechnology
Sector:
Healthcare
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1111 Dr. Frederik-Philips Boulevard
Montreal, QC H4M 2X6
Montreal, QC H4M 2X6
CIK: 0001408443
ISIN: CA59935V1076
CUSIP: 59935V107
